I
Ignacio Duran
Researcher at Services Hospital
Publications - 45
Citations - 1817
Ignacio Duran is an academic researcher from Services Hospital. The author has contributed to research in topics: Population & Atezolizumab. The author has an hindex of 11, co-authored 45 publications receiving 1202 citations. Previous affiliations of Ignacio Duran include University of Seville.
Papers
More filters
Journal ArticleDOI
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Thomas Powles,Ignacio Duran,Michiel S. van der Heijden,Yohann Loriot,Nicholas J. Vogelzang,Ugo De Giorgi,Stéphane Oudard,Margitta Retz,Daniel Castellano,Aristotelis Bamias,Aude Flechon,Gwenaelle Gravis,Syed A. Hussain,Toshimi Takano,Ning Leng,Edward E. Kadel,Romain Banchereau,Priti S. Hegde,Sanjeev Mariathasan,Na Cui,Xiaodong Shen,Christina Louise Derleth,Marjorie C. Green,Alain Ravaud +23 more
TL;DR: Atezolizumab was not associated with significantly longer overall survival than chemotherapy in patients with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1, thus precluding further formal statistical analysis.
Journal ArticleDOI
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Thomas Powles,Michiel S. van der Heijden,Daniel Castellano,Matthew D. Galsky,Yohann Loriot,Daniel P. Petrylak,Osamu Ogawa,Se Hoon Park,Jae-Lyun Lee,Ugo De Giorgi,Martin Bögemann,Aristotelis Bamias,Bernhard J. Eigl,Howard Gurney,Som D. Mukherjee,Yves Fradet,Iwona Skoneczna,Marinos Tsiatas,Andrey Novikov,Cristina Suarez,Andre P. Fay,Ignacio Duran,Andrea Necchi,Sophie Wildsmith,Philip He,Natasha Angra,Ashok K. Gupta,Wendy Levin,Joaquim Bellmunt,Jae-Lyun Lee,Hans Westgeest,Aude Flechon,Yen-Chuan Ou,Inkeun Park,Vsevolod Matveev,Begoña Perez-Valderrama,Susanna Cheng,Stephen Jay Frank,Urbano Anido,Alketa Hamzaj,Margitta Retz,Srikala S. Sridhar,Giorgio V. Scagliotti,Jens Voortman,Boris Alekseev,Anna Alyasova,Boris Komyakov,Herlinde Dumez,Michel Pavic,Go Kimura,Atsushi Mizokami,Susanne Osanto,Jose Angel Arranz,Djura Piersma,Sang Joon Shin,Oleg Karyakin,Ignacio Delgado,Jose Luis Gonzalez,See-Tong Pang,Anna Tran,Oleg Lipatov,Wen Pin Su,Thomas W. Flaig,Ajjai Alva,Hwa Park Kyong,Evgeny Kopyltsov,Elena Almagro,Monserrat Domenech,Yen-Hwa Chang,Brieuc Sautois,Andre Ravaux,Gerasimos Aravantinos,Vasileios Georgoulias,Sasja Mulder,Yu Jung Kim,Fabio Kater,Christine Chevreau,Scott T. Tagawa,Pawel Zalewski,Florence Joly,Gencay Hatiboglu,Luca Gianni,Franco Morelli,Rosa Tambaro,Yasuhiro Hashimoto,Alexander Nosov,Albert Font,Alejo Rodriguez-Vida,Robert Jones,Naveen S. Vasudev,Sandhya Srinivas,Jingsong Zhang,Thierry Gil,Daygen Finch,Marc-Oliver Grimm,Yu-Li Su,Simon Chowdhury,Christopher Hocking,Eugen Plas,Scott North,Niels Viggo Jensen,Christine Theodore,Florian Imkamp,Avivit Peer,Takashi Kobayashi,Hideki Sakai,Naoto Sassa,Kazuhiro Yoshimura,Maureen J.B. Aarts,Ana Ferreira Castro,Marlen Topuzov,Juan Francisco Rodriguez,Federico Vazquez,Yu-Chieh Tsai,Simon J. Crabb,Syed A. Hussain,Johanna C. Bendell,Marine Gross-Goupil,Gravis Gwenaelle,Raanan Berger,Galina Statsenko,Linda Evans,Alexandra Drakaki,Bradley Somer,Ian D. Davis,James Lynam,Giuliano Santos Borges,Aldo Dettino,Graziella Martins,Luis Eduardo Zucca,Mads Agerbæk,Haralambos Kalofonos,Eli Rosenbaum,Hideki Enokida,Hiroaki Kikukawa,Kazuo Nishimura,Satoshi Tamada,Motohide Uemura,Yamil Lopez,Jourik A. Gietema,Marcin Slojewski,Isabel Fernandes,Alexey Smolin,Danish Mazhar,Arash Rezazadeh Kalebasty,Bradley Carthon,Wolfgang Loidl,Fabio Franke,Gustavo Girotto,Nimira S. Alimohamed,Robyn Macfarlane,Helle Pappot,Guenter Niegisch,Dimitrios Mavroudis,Avishay Sella,Camillo Porta,Shin Ebara,Motonobu Nakamura,Wataru Obara,Norihiko Okuno,Nobuo Shinohara,Mikio Sugimoto,Akitaka Suzuki,Noriaki Tokuda,Hiroji Uemura,Akito Yamaguchi,Francisco Ramirez,Pawel Rozanowski,Paweł Wiechno,Bhumsuk Keam,Nikolay Kislov,Denis Plaksin,Irfan Cicin,Satish Kumar,Joseph Rosales,Ulka N. Vaishampayan,Stéphane Culine,Christos Papandreou,Taketoshi Nara,Mustafa Erman,Laurence Kreiger,Juliana Janoski,Diogo Rosa,Mariana Siqueira,Christina Canil,Lisa Sengeløv,Jean-Marc Tourani,Gaku Arai,Katsuyoshi Hashine,Mutsushi Kawakita,Noboru Nakaigawa,Hayahito Nomi,Hiroaki Shiina,Hiroyoshi Suzuki,Junji Yonese,Roberto Kuri,Eleazar Macedo,Samuel Rivera,Alberto Villalobos Prieto,Anna Polakiewicz-Gilowska,Renata Zaucha,Fabio Lopes,Roman Ponomarev,Mark Pomerantz,Shahrokh F. Shariat,Cynthia Luk,Krzysztof Lesniewski-Kmak +206 more
TL;DR: The overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab ( a CTLA-4 inhibitor), as a first-line treatment for metastatic urothelial carcinoma was assessed.
Journal ArticleDOI
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Cora N. Sternberg,Yohann Loriot,Nicholas D. James,Ernest Choy,Daniel Castellano,Fernando Lopez-Rios,Giuseppe Luigi Banna,Ugo De Giorgi,Cristina Masini,Aristotelis Bamias,Xavier Garcia del Muro,Ignacio Duran,Thomas Powles,Marija Gamulin,Friedemann Zengerling,Lajos Géczi,Craig Gedye,Sabine de Ducla,Simon Fear,Axel S. Merseburger +19 more
TL;DR: Efficacy overall and in the IMvigor211-like subgroup is consistent with previous pivotal anti-PD-L1/PD-1 urothelial carcinoma trials, and results support the use of atezolizumab in urinary tract carcinoma, including patients with limited treatment options.
Journal ArticleDOI
Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective - prospective observational study - a cohort from 4 European countries.
Herbert Hoefeler,Ignacio Duran,Guy Hechmati,C. Garzon Rodriguez,Diana Lüftner,John Ashcroft,Amit Bahl,C. Atchison,R. Wei,E. Thomas,V. Lorusso +10 more
TL;DR: All types of SREs are associated with substantial HRU burden, and prevention by using the best therapeutic options available may help to reduce the burden to patients and healthcare systems.
Journal ArticleDOI
Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
Michiel S. van der Heijden,Yohann Loriot,Ignacio Duran,Alain Ravaud,Margitta Retz,Nicholas J. Vogelzang,B. Nelson,Jingjing Wang,Xiaodong Shen,Thomas Powles +9 more
TL;DR: Atezolizumab is an anti-PD-L1 immune checkpoint inhibitor recommended for the treatment of locally advanced or metastatic urothelial carcinoma (mUC) after prior platinum-containing chemotherapy as mentioned in this paper.